Patent SG-11201810594R-A (SG)
Title: Nucleic acid molecules for reduction of papd5 or papd7 mrna for treating hepatitis b infection
Inventor: JAVANBAKHT HASSAN
IPC: C12Q1/68
Filed: 2017-06-19
Abstract: siPAPD5 + siPAPD7 -a- siPAPDS -•- siPAPD7 100 80 60 40 20 0 % in hibit ion HBs ( Ag ) A (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 21 December 2017 (21.12.2017) WIP0 I PCT omit VIII two Hol omiolimmoliflom (10) International Publication Number WO 2017/216390 Al (51) International Patent Classification: C12Q 1/70 (2006.01) C12N 15/113 (2010.01) C07K 16/00 (2006.01) C12Q 1/68 (2006.01) (21) International Application Number: PCT/EP2017/064980 (22) International Filing Date: 19 June 2017 (19.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 16175045.0 17 June 2016 (17.06.2016) EP (71) Applicant (for all designated States except US): F. HOFF- MANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH). (71) Applicant (for US only): HOFFMANN-LA ROCHE INC. [US/US]; Overlook at Great Notch, 150 Clove Road 8th Floor, Suite 8 - Legal Department, Little Falls, New Jer- sey 07424 (US). (72) Inventors: JAVANBAKHT, Hassan; Aeschenvorstadt 50, 4051 Basel (CH). MUELLER, Henrik; c/o F. Hoff- mann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). OTTOSEN, Soren; Gyngemose Parkvej 37, 4.tv, 2860 Soborg (DK). PEDERSEN, Lykke; Dalmosevej 20, 2400 Copenhagen NV (DK). (74) Agent: RUDOLPH HANSEN, Marianne; Grenzacher- strasse 124, 4070 Basel (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (54) Title: NUCLEIC ACID MOLECULES FOR REDUCTION OF PAPD5 OR PAPD7 MRNA FOR TREATING HEPATITIS B INFECTION Figure 7 B W O 20 17 / 216390 Al 10 100 nMol (siRNA) (57) : The present invention relates to a method for identifying a compound that prevents, ameliorates and/or inhibits a hepatitis B virus (HBV) infection, wherein a compound that reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7) is identified as a compound that prevents, ameliorates and/or inhibits a HBV infection. The invention also provides for inhibitors of PAPD5 or PAPD7 for use in treating and/or preventing a HBV infection; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of a HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection, and a method for monitoring the therapeutic success during the treatment of a HBV infection. [Continued on next page] WO 2017/216390 Al MIDEDIMOMOIDEIRMEM00110HEINIMOIHMEMOIS GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))